666260-75-9

Usage

Uses

Used in Pharmaceutical Industry:
GW 842166X is used as an analgesic agent for the treatment of inflammatory and neuropathic pain. Its high selectivity for the CB2 receptor makes it a promising candidate for pain management without the psychoactive side effects associated with CB1 receptor agonists.
Used in Immune System Regulation:
GW 842166X is used as an immune modulator, targeting the CB2 receptors predominantly found in immune cells, monocytes, and macrophages. This selective targeting allows for potential therapeutic applications in modulating immune responses and treating immune-related disorders.
Used in Neuropathic Pain Management:
GW 842166X is used as a neuroprotective agent for the treatment of neuropathic pain. Its ability to selectively activate CB2 receptors may provide a novel approach to managing neuropathic pain without the side effects of traditional opioids or other pain medications.

InChI:InChI=1/C18H17Cl2F3N4O2/c19-11-1-2-14(13(20)7-11)26-17-25-9-12(15(27-17)18(21,22)23)16(28)24-8-10-3-5-29-6-4-10/h1-2,7,9-10H,3-6,8H2,(H,24,28)(H,25,26,27)

Upstream product

• 554-00-7 2,4-Dichloroaniline 
• 130290-79-8 4-tetrahydropyranmethylamine 
• 666260-42-0 2-(2,4-dichlorophenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid 
• 666260-76-0 methyl 2-(2,4-dichlorophenyl-amino)-4-trifluoromethyl-pyrimidine-5-carboxylate 
• 175137-27-6 methyl 2-chloro-4-(trifluoromethyl)pyrimidine 5-carboxylate 

Relevant academic research and scientific papers

Discovery of 2-[(2,4-dichlorophenyl)amino]-N-[(tetrahydro-2H-pyran-4-yl) methyl]-4-(trifluoromethyl)-5-pyrimidinecarboxamide, a selective CB2 receptor agonist for the treatment of inflammatory pain

Selective CB2 receptor agonists are promising potential therapeutic agents for the treatment of inflammatory and neuropathic pain. A focused screen identified a pyrimidine ester as a partial agonist at the CB2 receptor with micromolar potency. Subsequent lead optimization identified 35, GW842166X, as the optimal compound in the series. 35 has an oral ED50 of 0.1 mg/kg in the rat FCA model of inflammatory pain and was selected as a clinical candidate for this indication.

COMBINATION OF CB2 MODULATORS AND PDE4 INHIBITORS FOR USE IN MEDICINE

Combination of one or more CB2 modulators such as a compound of formula (I), (II) and (III); and one more PDE4 inhibitors are useful of treating conditions which are mediated by the activity of CB2 receptors or conditions which are mediated by PDE4, such

PYRIMIDINE DERIVATIVES AND THEIR USE AS CB2 MODULATORS

This relates to novel pyrimidine derivatives, pharmaceutical compositions containing these compounds and their use in the treatment of diseases, particularly pain, which diseases are caused directly or indirectly by an increase or decrease in activity of